|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...99100101102103104105106107108109110111» |
- arsenic trioxide / Generic mfg.
Enrollment change, Metastases: Trisenox (clinicaltrials.gov) - Apr 12, 2012
P2, N=5, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=10 --> 5
- Enrollment change: Comparison of Standard of Care or Treatment on Protocol (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=13, Terminated, Sponsor: New Mexico Cancer Care Alliance
N=10 --> 5 N=2000 --> 13
- Enrollment closed, Surgery: Dilators for Dyspareunia Prevention (clinicaltrials.gov) - Apr 12, 2012
P4, N=54, Active, not recruiting, Sponsor: Medstar Research Institute
N=2000 --> 13 Recruiting --> Active, not recruiting
- | New P4 trial: CANTAPOR: Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol (clinicaltrials.gov) - Apr 11, 2012
P4, N=120, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- Follistim AQ Cartridge (follitropin beta) / Organon
New P4 trial, Head-to-Head: CLOVANT: RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders (clinicaltrials.gov) - Apr 11, 2012
P4, N=106, Suspended, Sponsor: Weill Medical College of Cornell University
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P3 trial: The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) (clinicaltrials.gov) - Apr 11, 2012
P3, N=150, Completed, Sponsor: Nik Hazlina
- | Vynfinit (vintafolide) / Novartis
Enrollment change, Metastases: Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) (clinicaltrials.gov) - Apr 10, 2012
P2, N=49, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=68 --> 49
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial, Metastases: A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients (clinicaltrials.gov) - Apr 10, 2012
P2, N=11, Completed, Sponsor: Novartis Pharmaceuticals
- | Vynfinit (vintafolide) / Novartis
Trial completion, Metastases: Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) (clinicaltrials.gov) - Apr 10, 2012
P2, N=49, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=68 --> 49 Active, not recruiting --> Completed
- Enrollment change: Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group (clinicaltrials.gov) - Apr 9, 2012
P=N/A, N=781, Completed, Sponsor: Taipei Medical University WanFang Hospital
Active, not recruiting --> Completed N=1000 --> 781
- ||| Enrollment change: Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM] (clinicaltrials.gov) - Apr 9, 2012
P4, N=1000, Recruiting, Sponsor: University of California, San Francisco
N=1000 --> 781 N=2000 --> 1000
- Trial completion: Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group (clinicaltrials.gov) - Apr 9, 2012
P=N/A, N=781, Completed, Sponsor: Taipei Medical University WanFang Hospital
N=2000 --> 1000 Active, not recruiting --> Completed
- azithromycin / Generic mfg.
Trial completion: Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger (clinicaltrials.gov) - Apr 9, 2012
P4, N=1139, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Trial completion, Metastases: ET743-OVA-301: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer (clinicaltrials.gov) - Apr 9, 2012
P3, N=672, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment change: MiCo - Mirena or Conventional Medical Treatment for Menorrhagia (clinicaltrials.gov) - Apr 8, 2012
P=N/A, N=1211, Completed, Sponsor: Bayer
Active, not recruiting --> Completed N=900 --> 1211
- | Enrollment open, Preclinical: Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients (clinicaltrials.gov) - Apr 8, 2012
P3, N=280, Recruiting, Sponsor: KK Women's and Children's Hospital
N=900 --> 1211 Not yet recruiting --> Recruiting
- ||| Trial completion: MiCo - Mirena or Conventional Medical Treatment for Menorrhagia (clinicaltrials.gov) - Apr 8, 2012
P=N/A, N=1211, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Trial completion, Metastases: Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants (clinicaltrials.gov) - Apr 4, 2012
P3, N=7466, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || New P3 trial: DITTO: Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging (clinicaltrials.gov) - Apr 3, 2012
P3, N=80, Recruiting, Sponsor: University of Nottingham
- |||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Apr 3, 2012
P2, N=450, Recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=5, Completed, Sponsor: AHS Cancer Control Alberta
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial suspension: WSW: Sexually Transmitted Infections Among African American Women Who Have Sex With Women (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=300, Suspended, Sponsor: University of Mississippi Medical Center
Recruiting --> Completed Recruiting --> Suspended
- ||| Erivedge (vismodegib) / Roche
Trial initiation date: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission (clinicaltrials.gov) - Apr 1, 2012
P2, N=104, Completed, Sponsor: Genentech
Recruiting --> Suspended Initiation date: Sep 2008 --> Dec 2008
- Trial completion: Chlamidia Antibodies Test for Tubal Factor Screening (clinicaltrials.gov) - Mar 29, 2012
P=N/A, N=60, Completed, Sponsor: Instituto Valenciano de Infertilidad, Spain
Initiation date: Sep 2008 --> Dec 2008 Recruiting --> Completed
- Enrollment change: The Effectiveness of Vestibulectomy (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=40, Completed, Sponsor: Western Galilee Hospital-Nahariya
Recruiting --> Completed N=100 --> 40
- || Zorbtive (somatropin) / EMD Serono
Enrollment change, Compliance: Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=834, Completed, Sponsor: Merck KGaA
N=100 --> 40 N=630 --> 834
- Trial completion: The Effectiveness of Vestibulectomy (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=40, Completed, Sponsor: Western Galilee Hospital-Nahariya
N=630 --> 834 Recruiting --> Completed
- dactolisib (RTB101) / Adicet Bio
Trial withdrawal, Metastases: BEZ235 Trial in Patients With Advanced Endometrial Carcinoma (clinicaltrials.gov) - Mar 27, 2012
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Withdrawn
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Metastases: BEZ235 Trial in Patients With Advanced Endometrial Carcinoma (clinicaltrials.gov) - Mar 27, 2012
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=140 --> 0
- Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (clinicaltrials.gov) - Mar 27, 2012
P2, N=21, Completed, Sponsor: University of Washington
N=140 --> 0 N=30 --> 21
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (clinicaltrials.gov) - Mar 27, 2012
P2, N=21, Completed, Sponsor: University of Washington
N=30 --> 21 Active, not recruiting --> Completed
- || Preclinical, Enrollment change: A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=356, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed N=500 --> 356
- ||| Trial completion, Preclinical: A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=356, Completed, Sponsor: Merck KGaA
N=500 --> 356 Active, not recruiting --> Completed
- carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial termination, Metastases: Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer (clinicaltrials.gov) - Mar 26, 2012
P2, N=22, Terminated, Sponsor: Korea Cancer Center Hospital
Active, not recruiting --> Completed Recruiting --> Terminated; This study stopped due to slow accrual.
- | cisplatin / Generic mfg.
Enrollment change, Metastases: Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer (clinicaltrials.gov) - Mar 26, 2012
P3, N=104, Completed, Sponsor: Korea Cancer Center Hospital
Recruiting --> Terminated; This study stopped due to slow accrual. N=150 --> 104
- carboplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Metastases: Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer (clinicaltrials.gov) - Mar 26, 2012
P2, N=22, Terminated, Sponsor: Korea Cancer Center Hospital
N=150 --> 104 N=44 --> 22
- estradiol valerate / Generic mfg.
Trial completion: Pretreatment With Estradiol Valerate (clinicaltrials.gov) - Mar 26, 2012
P4, N=80, Completed, Sponsor: Universitair Ziekenhuis Brussel
N=44 --> 22 Recruiting --> Completed
- clomifene citrate / Generic mfg.
Trial completion: cc versus FSH: Comparison of Clomiphene Citrate and Gonadotropins in Ovulation Induction Cycles (clinicaltrials.gov) - Mar 26, 2012
P4, N=40, Completed, Sponsor: Universitair Ziekenhuis Brussel
Recruiting --> Completed Recruiting --> Completed
- cabergoline / Generic mfg.
Clinical: Ovarian Hyperstimulation Syndrome and Cabergoline (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=40, Completed, Sponsor: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
- |||||||||| Norditropin (somatropin) / Novo Nordisk
New P3 trial: Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency (clinicaltrials.gov) - Mar 25, 2012
P3, N=168, Completed, Sponsor: Novo Nordisk
- || New P3 trial, Preclinical: Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization (clinicaltrials.gov) - Mar 25, 2012
P3, N=400, Completed, Sponsor: Instituto Valenciano de Infertilidad, Spain
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
New P2 trial: Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients (clinicaltrials.gov) - Mar 25, 2012
P2, N=1, Terminated, Sponsor: Cerulean Pharma Inc.
- sirolimus / Generic mfg.
Enrollment open: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Not yet recruiting --> Recruiting
- Preclinical, Enrollment change: Optimizing the Temperature for Embryo Culture in In Vitro Fertilization (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: Reproductive Medicine Associates of New Jersey
Not yet recruiting --> Recruiting N=200 --> 100
- || Enrollment change: Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=200, Active, not recruiting, Sponsor: Reproductive Medicine Associates of New Jersey
N=200 --> 100 N=500 --> 200
- Preclinical: Weight Management Intervention for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF) (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=334, Recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
- motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 22, 2012
P1, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=500 --> 200 N=30 --> 36
- Surgery: Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery (clinicaltrials.gov) - Mar 21, 2012
P=N/A, N=130, Recruiting, Sponsor: Swedish Medical Center
- ||||||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Trial completion: MEGASET: MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer (clinicaltrials.gov) - Mar 21, 2012
P3, N=749, Completed, Sponsor: Ferring Pharmaceuticals
N=30 --> 36 Active, not recruiting --> Completed
- cisplatin / Generic mfg., paclitaxel / Generic mfg., acetylcysteine solution / Generic mfg.
Trial suspension: N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer (clinicaltrials.gov) - Mar 21, 2012
P1, N=33, Suspended, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Recruiting --> Suspended